Literature DB >> 21622696

The power of Pasteur's quadrant: cardiovascular disease at the turn of the century.

Richard I Levin1, Glenn I Fishman.   

Abstract

During the life span of The FASEB Journal, the decline in cardiovascular mortality was astonishing as the fundamental bases of the complex syndromes of cardiovascular disease were illuminated. In this Silver Anniversary Review, we highlight a few pivotal advances in the field and relate them to research in Pasteur's quadrant, the region of investigation driven by both a desire for fundamental understanding and the consideration of its use. In the second half of the 20th century, we advanced from little pathophysiologic understanding to a near-complete understanding and effective, evidence-based therapeutics for vascular disorders and a similar development of pharmacotherapy to address heart failure, primarily through agents that antagonize the excessive concentration of circulating neurohumoral agents. In the current era, we have witnessed "the rise of the machines," from stents to cardiac resynchronization therapy. The next wave of treatments will build on an increasingly sophisticated understanding of the molecular determinants of cardiovascular disorders. We briefly consider the promise of regenerative medicine and are intrigued by the possibility for the direct reprogramming of resident cardiac fibroblasts into cardiomyocytes. As for the future, genomic profiling should help physicians recommend individualized risk factor modification targeted to prevent specific manifestations of cardiovascular disease. Transcriptional and biomarker analyses will almost surely be used individually to tailor therapy for those at risk of or experiencing cardiovascular disease. Given the ongoing exponential expansion of scientific knowledge, all of human ingenuity will be needed to fully utilize the power of Pasteur's quadrant and to unleash another quarter century in cardiology as scientifically fruitful and effective on human health as the last.

Entities:  

Mesh:

Year:  2011        PMID: 21622696      PMCID: PMC3219216          DOI: 10.1096/fj.11-0604ufm

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  39 in total

1.  Simon Dack Lecture. The genomic basis of myocardial infarction.

Authors:  Eric J Topol
Journal:  J Am Coll Cardiol       Date:  2005-09-28       Impact factor: 24.094

Review 2.  Transesophageal echocardiography as a tool in the evaluation of patients with embolic disorders.

Authors:  I Kronzon; P A Tunick
Journal:  Prog Cardiovasc Dis       Date:  1993 Jul-Aug       Impact factor: 8.194

3.  Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy.

Authors:  F Waagstein; A Hjalmarson; E Varnauskas; I Wallentin
Journal:  Br Heart J       Date:  1975-10

4.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

5.  An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans.

Authors:  N C Lau; L P Lim; E G Weinstein; D P Bartel
Journal:  Science       Date:  2001-10-26       Impact factor: 47.728

6.  An extensive class of small RNAs in Caenorhabditis elegans.

Authors:  R C Lee; V Ambros
Journal:  Science       Date:  2001-10-26       Impact factor: 47.728

Review 7.  Pathophysiology of coronary artery disease.

Authors:  Peter Libby; Pierre Theroux
Journal:  Circulation       Date:  2005-06-28       Impact factor: 29.690

8.  Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors.

Authors:  Masaki Ieda; Ji-Dong Fu; Paul Delgado-Olguin; Vasanth Vedantham; Yohei Hayashi; Benoit G Bruneau; Deepak Srivastava
Journal:  Cell       Date:  2010-08-06       Impact factor: 41.582

9.  Advanced heart failure treated with continuous-flow left ventricular assist device.

Authors:  Mark S Slaughter; Joseph G Rogers; Carmelo A Milano; Stuart D Russell; John V Conte; David Feldman; Benjamin Sun; Antone J Tatooles; Reynolds M Delgado; James W Long; Thomas C Wozniak; Waqas Ghumman; David J Farrar; O Howard Frazier
Journal:  N Engl J Med       Date:  2009-11-17       Impact factor: 91.245

10.  Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction.

Authors:  M A DeWood; J Spores; R Notske; L T Mouser; R Burroughs; M S Golden; H T Lang
Journal:  N Engl J Med       Date:  1980-10-16       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.